Skip to main content
Cheryl Willman, MD, Pathology, Albuquerque, NM

Cheryl Willman MD

Pathology•Albuquerque, NM

Anatomic Pathology, Clinical Pathology

Professor, Pathology, University of New Mexico School of Medicine

Join to View Full Profile

  • 2325 Camino de Salud NEUNM Cancer Research Treatment CenterAlbuquerque, NM 87131

  • Phone+1 505-272-5622

Are you Dr. Willman?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
Claim this profileNot you? Find your profile

Summary

  • Dr. Cheryl Willman, MD is a board certified pathologist in Albuquerque, New Mexico. She is currently licensed to practice medicine in New Mexico. She is a Professor at University of New Mexico School of Medicine.

Education & Training

  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineResidency, Pathology-Anatomic and Clinical, 1981 - 1984
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Pathology-Anatomic and Clinical, 1981 - 1981
  • Mayo Clinic College of Medicine
    Mayo Clinic College of MedicineClass of 1981

Certifications & Licensure

  • NM State Medical License
    NM State Medical License 1985 - 2025
  • Anatomic Pathology
    American Board of Pathology Anatomic Pathology

Publications & Presentations

PubMed

Press Mentions

  • Mayo Clinic to Expand Access to State-of-the-Art Cancer Care Through Transformational Gift
    Mayo Clinic to Expand Access to State-of-the-Art Cancer Care Through Transformational GiftSeptember 10th, 2024
  • Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
    Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform TreatmentApril 4th, 2024
  • FDA’s Fashoyin-Aje: Draft Guidance on Accelerated Approval Urges Reliance on Randomized Controlled Trials
    FDA’s Fashoyin-Aje: Draft Guidance on Accelerated Approval Urges Reliance on Randomized Controlled TrialsMarch 31st, 2023
  • Join now to see all

Dr. Cheryl Willman, Dr. Cheryl Willman, MD, Dr. C Willman